Background. New vaccines against tuberculosis (TB) are urgently needed because the only available vaccine, Mycobacterium bovis bacillus Calmette-Guérin (BCG), fails to protect against pulmonary TB in adults. The recombinant DureC hly1 BCG (rBCG) is more efficient than parental BCG (pBCG) against pulmonary TB in preclinical studies and has proven safe and immunogenic in phase I clinical trials.
Every year, up to 2 million people die from tuberculosis (TB) [1] . The only available vaccine against TB is Mycobacterium bovis bacillus Calmette-Guérin (BCG), which was used in humans for the first time in 1921 [2] . To date, 4 billion doses of BCG have been administered, making it the most widely used human vaccine worldwide [3] . Yet, we are still far from having achieved eradication of TB. BCG vaccination prevents tuberculous meningitis and miliary TB in infants [4] . However, protection against other forms of TB, notably pulmonary TB in adolescents and adults, is inconclusive, as emphasized by a meta-analysis that revealed protective efficacies ranging from 0% to 80% [5] . Therefore, new vaccines against TB are urgently needed. At present, new vaccination strategies against TB include recombinant BCG to replace or boost canonical BCG as well as subunit vaccines and nonreplicating viral vector-based vaccines to booster BCG prime [6, 7] .
Identification of the immunologic mechanisms that underly protection can facilitate the rational design of novel vaccination strategies for TB prevention. Moreover, biomarkers indicative for protective immunity could serve as surrogate endpoints of clinical outcome in TB vaccine efficacy trials and thus reduce the duration of those trials as well as facilitate testing of larger numbers of vaccine candidates. Observational studies of newly infected, healthy contacts of patients with TB and BCG-vaccinated infants have been initiated to define such biomarkers [8] . Despite extensive research on the immune response to TB, the fundamental elements of protective memory have yet to be elucidated. After BCG vaccination, antigen-specific memory CD4 T cells are difficult to detect because of the paucity of immunodominant antigens. Currently, the most widely used biomarkers are based on elevated frequencies of CD4 T cells producing interferon c (IFN-c). Increasing evidence questions the value of IFN-c as correlate of protection in TB [9, 10] . Undoubtedly IFN-c does play a crucial role in defense against Mycobacterium tuberculosis (MTB) infection [11] , but determination of IFN-c levels alone can no longer be considered a reliable marker of protective immunity.
We constructed a recombinant DureC hly1 BCG (rBCG) strain that expresses membrane-perforating listeriolysin (hly) of Listeria monocytogenes and is devoid of urease C. This rBCG construct induces superior protection against aerogenic challenge with MTB compared with parental BCG (pBCG) [12] . The rBCG construct has successfully proven to be safe and immunogenic in phase I clinical trials. In this study, we compared immune responses after vaccination with rBCG or pBCG in an attempt to identify biomarkers that correlate with protection in a mouse model of TB infection. Our data reveal that rBCG concomitantly induced a balanced combination of type 1 and type 17 cytokine responses, whereas pBCG-induced immunity comprised a type 1 response only. The results of further experiments emphasize the unique role of interleukin (IL) 17 in improved protection against TB and hence point to general mechanisms for consideration in future vaccine design against this major health threat.
MATERIALS AND METHODS

Mice
Female BALB/c mice were kept under specific pathogen-free conditions. Experiments were conducted with the approval of the Landesamt für Gesundheit und Soziales (State Office of Health and Social Affairs, Berlin, Germany).
Bacteria
The MTB strains H37Rv, pBCG, and rBCG that were used have been described elsewhere [12] . Bacteria were grown in Middlebrook 7H9 agar supplemented with glycerol, 0.05% Tween 80, and albumin dextrose catalase. Midlogarithmic cultures were harvested and stored at -80°C. Stocks were titrated prior to use.
Vaccination and MTB Infection
The pBCG or rBCG (10 6 colony-forming units [CFUs]) were administered subcutaneously. Aerogenic infection was performed using a Glas-Col inhalation exposure system. Bacterial burdens were assessed by mechanical disruption of removed organs in phosphate-buffered saline (PBS) with 0.5% vol/vol Tween 80 and plating serial dilutions onto Middlebrook 7H11 agar plates supplemented with oleic acid-albumin-dextrose-catalase. Colonies were counted after 3 weeks.
Cell Isolation, Stimulations, and Flow Cytometry Cells were purified as described elsewhere [13] . Cells were stimulated with 50 lg/mL purified protein derivative (PPD; SSI) for 20 hours for analysis by multiplex assay or for 6 hours in the presence of 25 lg/mL brefeldin A for intracellular cytokine staining. The following antibodies were used: CD4, IFN-c, IL-2, Ly6G/C, CD11b, cd-T-cell receptor, and CD49b (eBioscience). CD8a, tumor necrosis factor a (TNF-a), CD16/CD32, F4/80, and CD11c were purified from hybridoma supernatants and fluorescently labeled. IL-17 was obtained from BD Biosciences. Cells were analyzed using a FACSCanto II or LSRII and FACSDiva software (BD Biosciences). Cytokines were measured using the Bio-Plex Mouse Th1/Th2, IL-17, and IL-6 bead-based immunoassays (Bio-Rad). IL-21 and IL-22 were measured by enzyme-linked immunosorbent assay (R&D systems).
Peritoneal Lavage
The pBCG or rBCG was freshly prepared from midlogarithmic cultures; 10 6 CFUs were administered intraperitoneally. Recruited cells were obtained from the peritoneal cavity by injection of 5 mL PBS and analyzed by flow cytometry. Cytokine and chemokine levels were determined using the Bio-Plex Mouse Cytokine 23-plex kit (Bio-Rad).
RESULTS
Type 1 and Type 17 Cytokine Responses After rBCG and pBCG Vaccination
In an attempt to elucidate the immune mechanisms relevant to TB vaccine efficacy, we compared immune responses to rBCG and pBCG in mice. Superior protective efficacy of rBCG had been originally determined after intravenous immunization [12] . Subcutaneous administration of rBCG induced comparable levels of protection and retained the superior efficacy of rBCG over pBCG ( Figure 1 ). We analyzed long-term memory responses 83 days after subcutaneous vaccination with rBCG or pBCG. Cells were restimulated with PPD, and supernatants were analyzed by multiplex assays for cytokines. Immunization with rBCG induced significantly higher cytokine production by cells isolated from the lung compared with pBCG ( Figure 1 ). These cytokines included IFN-c, IL-2, IL-6, and granulocytemacrophage colony-stimulating factor (GM-CSF). In contrast, levels of the type 2 cytokines IL-4, IL-5, and IL-10 were not increased above background levels (data not shown). Intriguingly, approximately 3-fold higher IL-17 concentrations were produced by lung cells from rBCG-vaccinated mice. Note that only a few cells could be isolated from the lungs of uninfected mice. Consequently, overall cytokine concentrations in lungs were lower than those in spleens, where 10-fold higher cell densities could be used for stimulation ( Figure 1 [14] . We compared antigen-specific T-cell responses in vaccinated animals upon aerosol infection with virulent MTB, 7 days after infection. Marked production of IFN-c, IL-17, IL-2, and GM-CSF by lung cells from rBCG-vaccinated mice was detected 20 hours after restimulation with PPD ( Figure 2 ). In contrast, these cytokines were barely secreted by cells from pBCG-vaccinated mice. In nonvaccinated animals infected with MTB, cytokine production levels were below the detection limit, in agreement with previous reports that MTBspecific T cells do not appear before 3 weeks after MTB infection [14] . Type 2 cytokines IL-4, IL-5, and IL-10 were not detected, and levels of TNF-a, IL-12p70, and IL-6 were only ) of MTB, and the bacterial burden was determined 90 days after infection. The cardiac lung lobe was homogenized; the remaining material was used for in vitro restimulation assays. Statistical significance was determined by the Mann-Whitney test with 2-tailed P values. *P ,.05; **P ,.01. Data are representative of 3 experiments with similar results. B, C, Responses in lungs and spleens, respectively, 83 days after subcutaneous vaccination with rBCG or pBCG. A total of 2.5 3 10 5 cells (lung) or 2 3 10 6 cells (spleen) were restimulated with purified protein derivative for 20 hours, and the supernatants were analyzed by multiplex assays. Cytokine concentrations are depicted as means (6 SEM) of 4 independent experiments with 3 replicates each. Background cytokine production levels from medium controls were subtracted. Analysis of variance and the Bonferroni multiple comparison test were applied for statistical analysis. *P , .05; **P , .01. Abbreviations: GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-c, interferon c; IL-2, interleukin 2; IL-6, interleukin 6; IL-17, interleukin 17; NIL, none; TNF-a, tumor necrosis factor a. 5 cells were stimulated with purified protein derivative (PPD) for 20 hours, and the supernatants were analyzed by multiplex assay. Cytokine concentrations are depicted as means (6 SEM) of 2 independent experiments with 3 replicates each. Background cytokine production levels from medium controls were subtracted. B, Analysis of cells restimulated with PPD for 6 hours in the presence of brefeldin A by multicolor flow cytometry. Frequencies of responding CD4 T cells are depicted as means (6 SEM) of 3 independent experiments with 3 replicates each. Analysis of variance and the Bonferroni multiple comparison test were applied for statistical analysis. *P , .05; **P , .01; ***P , .001. Abbreviations: GM-CSF, granulocytemacrophage colony-stimulating factor; IFN-c, interferon c; IL-2, interleukin 2; IL-17, interleukin 17; NIL, none; pBCG, parental BCG; TNF-a, tumor necrosis factor a.
barely above background levels at this early time point after MTB challenge (data not shown).
We determined cytokine production levels by lung T cells by flow cytometry 7 days after MTB infection (Figure 2 ). Cells were stimulated with PPD for 6 hours, followed by intracellular cytokine staining for IL-2, IL-17, IFN-c, and TNF-a. In nonvaccinated control mice, a small proportion of CD4 T cells produced IL-2, TNF-a, or IFN-c. In vaccinated mice, CD4 6 cells were restimulated with PPD for 20 hours, and the supernatants were analyzed by multiplex assays. Cytokine concentrations are depicted as means (6 SEM) of 4 independent experiments with 3 replicates each. Background cytokine production levels from medium controls were subtracted. B, Analysis of cells restimulated with PPD for 6 hours in the presence of brefeldin A by multicolor flow cytometry. Frequencies of responding CD4 T cells are depicted as means (6 SEM) of 3 independent experiments with 3 replicates each. Analysis of variance and the Bonferroni multiple comparison test were applied for statistical analysis. *P , .05; **P , .01; ***P , .001. Abbreviations: GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-c, interferon c; IL-2, interleukin 2; IL-17, interleukin 17; NIL, none; pBCG, parental BCG; TNF-a, tumor necrosis factor a. T cells secreted IL-2, IFN-c, TNF-a, and IL-17. Frequencies of single-cytokine-producing cells were highest, albeit not significant, in the rBCG group. In vaccinated animals, we detected multifunctional T cells, which are implicated in protective immunity [15] . Multiple-cytokine-producing T cells were predominantly IL-2 Splenic T cells produced similar cytokine patterns to those of pulmonary T cells (Figure 3 ). IL-2 and GM-CSF production was significantly higher in rBCG-vaccinated animals than in pBCG-vaccinated animals and below the detection level in nonvaccinated controls, even though a small percentage of CD4 T cells produced IFN-c in nonvaccinated controls. In sum, vaccination with either pBCG or rBCG induced CD4 T cells secreting IFN-c and TNF-a with higher frequencies of single and multiple producers in rBCG-vaccinated mice compared with pBCG-vaccinated mice. This is consistent with the finding that IL-17 accelerates recruitment of IFN-c-producing cells to the site of infection [14] . Different levels of cytokine production and frequencies of producer cells were not due to different bacterial burdens, as confirmed by comparable numbers of CFUs in lungs and spleens (data not shown). Total numbers of T-regulatory cells increased upon infection to a comparable degree in vaccinated groups (data not shown). At 7 days after infection, CD4 T cells were the main cytokine producers; cytokine-producing CD8 T cells were detected with lower frequencies in lungs and spleens albeit with similar patterns (data not shown).
Vaccination With rBCG Confers Potent Immune Responses During Persistent Infection
We analyzed MTB-specific immune responses 90 days after infection, when lung bacterial burdens were approximately 10-fold lower in rBCG-immunized animals than in the pBCG group and 100-fold lower than in nonvaccinated controls. Cells from lungs of vaccinated mice and untreated controls were restimulated with PPD for 20 hours, and cytokine concentrations were measured by multiplex assays (Figure 4 ). Cytokines detected upon restimulation were predominantly of type 1. However, we could not detect differences in IFN-c or IL-17 levels between the 2 vaccinated groups during persistent infection. In contrast, amounts of IL-2, IL-6, GM-CSF, and TNF-a were higher in rBCG-vaccinated mice. In all groups, IL-4 and IL-5 levels were below the detection limit (data not shown). In addition, analysis of lung cells by multicolor flow cytometry revealed predominantly cytokine-producing CD4 T cells during persistent infection ( Figure 4 ). CD4 T cells secreting only IFN-c were detected in all groups with similar frequencies. Upon vaccination, CD4 T cells producing IL-2, IFN-c, TNF-a, or IL-17 in different combinations could also be detected. Intriguingly, frequencies of responding CD4 T cells did not differ significantly between rBCG-and pBCG-vaccinated mice despite higher concentrations of IL-2 and TNF-a in supernatants. We assume that both vaccines increased frequencies of antigen-specific CD4 T cells in the lung during persistent MTB infection, with rBCGinduced T cells becoming more potent cytokine producers. CD8 T cells almost exclusively secreted IFN-c with comparable frequencies in all groups, and multifunctional CD8 T-cell counts were barely above the background (data not shown).
Vaccination Causes IL-22 but Not IL-21 Production
Th17 cells can produce additional effector cytokines such as IL-21 [16] and IL-22 [17] . IL-22-producing cells have been identified in patients with TB, but these cells seem to be distinct from IL-17-producing cells [18] . We did not detect IL-21 after PPD stimulation of cells from vaccinated and subsequently MTB-infected mice ( Figure 5 ). IL-22 was produced at elevated concentrations by PPD-stimulated splenocytes ( Figure 5 ) in immunized mice, but concentrations did not further increase early after infection with MTB. IL-22 production by lung cells was only observed in the rBCG-vaccinated group and decreased after aerosol MTB infection. 2 ) remained unchanged. In sum, no significant differences in antigen-presenting cell (APC) recruitment were detectable between the rBCG and pBCG groups ( Figure 6 ).
Peritoneal cells harvested 5 hours after vaccination were subjected to polyclonal stimulation ( Figure 6 ) with aCD3/ aCD28 antibodies. Frequencies of CD4 T cells and natural killer (NK) cells were comparable between all groups, as were levels of IFN-c and IL-17 production. Six days after administration, these cells increased numerically and reached the highest frequencies in the rBCG group ( Figure 6 ). PPD was used for restimulation of cells on day 6. CD4 T cells did not produce appreciable amounts of IFN-c or IL-17, whereas a substantial proportion of NK cells produced IFN-c after rBCG administration. The cd T cells have been identified as a major source of early IL-17 in TB [19] . Increased, albeit not significant, proportions of cd T cells producing IFN-c were identified 5 hours after administration of rBCG. This cell population further increased numerically, and markedly higher frequencies of cd T cells producing IL-17 were detected in the rBCG group 6 days after vaccination. CD8 T cells were not detected in the peritoneal cavity in any of the groups. In addition, we analyzed cytokines and chemokines in the from the peritoneum 5 hours (upper panel) and 6 days (lower panel) after intraperitoneal administration of rBCG or pBCG. B, Intracellular cytokine staining (ICS) of T-cell populations 5 hours after injection. Cells were stimulated with aCD3/aCD28 antibodies for 18 hours in the presence of brefeldin A. C, ICS of T-cell populations 6 days after administration. Cells were restimulated with purified protein derivative for 18 hours in the presence of brefeldin A. Data are presented as a summary of 3 independent experiments with 5 mice per group. Horizontal lines indicate the median values. Analysis of variance and the Bonferroni multiple comparison test were applied for statistical analysis. *P , .05; **P , .01. D, Cytokines and chemokines detected in peritoneal lavage fluid analyzed by multiplex assay, depicted as mean concentrations (6 SEM); summary of 3 independent experiments with 5 mice per group. Abbreviations: DC, dendritic cells; G-CSF, granulocyte colony-stimulating factor; IFN-c, interferon c; IL-12p40, interleukin 12p40; IL-17, interleukin 17; KC, keratinocyte chemoattractant; MCP-1, monocyte chemoattractant protein-1; MIP-1a, macrophage inflammatory protein-1a; PBS, phosphate-buffered saline. peritoneal cavity by multiplex assay of peritoneal lavage fluid (Figure 6 ). Levels of monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1a, granulocyte colony-stimulating factor (G-CSF), and keratinocyte chemoattractant (KC) were rapidly increased upon injection; levels of eotaxin remained unchanged and IL-12p40 was detected in higher concentrations after 6 days. However, we could not detect any significant differences in these measures between the pBCG and rBCG groups. Levels of IL-1b, IL-6, IL-9, IL-13, MIP-1b, and regulated upon activation, normal T-cell expressed and secreted could also be measured in comparable concentrations, whereas IL-12p70, IFN-c, IL-1a, IL-2, IL-3 , IL-4, IL-5, IL-10, IL-17, GM-CSF, and TNF-a concentrations were below the detection limit (data not shown). Thus, rBCG and pBCG induced recruitment of APCs as well as chemokine and cytokine production at the site of administration to a similar extent. Intriguingly, proportions of cd T cells secreting IL-17 and NK cells producing IFN-c were most abundant after rBCG administration.
DISCUSSION
The identification of biomarkers is crucial for rational design of novel TB vaccines. These markers could also form the basis for definition of surrogate markers to predict endpoints of clinical outcome in TB vaccine efficacy trials and thus provide guidelines for improvement of current vaccine candidates. The importance of key cytokines that activate macrophage antimycobacterial capacities including IFN-c [20] and TNF-a [21] , and the necessity for IL-2 in the expansion of memory cells [22] , are well established and thus commonly used to monitor TB vaccine trials.
In an attempt to better understand immune mechanisms underlying the superior protection of rBCG over pBCG and to harness our knowledge for identification of biomarkers of vaccine efficacy, we compared long-term memory immune responses elicited by rBCG and its parental strain, pBCG. Responses differed in both quantitative and qualitative terms. We detected an increased abundance of type 1 cytokines as well as IL-17 in the lung following vaccination with rBCG. Analysis of vaccine-induced immune responses in the lungs is obviously not feasible in the context of clinical trials. Therefore, we also analyzed systemic long-term memory responses. Intriguingly, comparable concentrations of type 1 promoting cytokines were detected in both pBCG and rBCG groups. In contrast, IL-17 production by splenocytes was significantly elevated upon rBCG vaccination. Thus, we conclude that the systemic release of IL-17, rather than of IFN-c or IL-2, qualified as a potential marker of superior protection induced by rBCG.
Th17 cells contribute to antimicrobial defense by attracting and activating neutrophils [23] , which are among the first cells recruited in response to IL-17. It has been shown that IL-17 is dispensable during primary MTB infection [24, 25] but gains importance in memory responses [14] . In addition, recent reports on the expression of CCR6 on human Th17 cells [26, 27] point to a positive feedback loop, because CCR6 is the receptor for CCL20 produced by neutrophils [28] and CCL20-CCR6 has been implicated in immunopathogenesis of TB [29] . Thus, type 17 cytokines could promote enhanced recruitment of antigenspecific memory T cells to the sites of bacterial residence. Analysis of vaccine-induced immune responses 7 days after infection with MTB revealed that vaccination with rBCG indeed led to an enhanced early response of effector cells at the sites of bacterial replication. We observed increased frequencies of antigen-specific CD4 T cells and elevated production of IL-2, IL-17, IFN-c, and GM-CSF by lung and spleen cells. Multifunctional CD4 T cells coproducing IL-2, IFN-c, and TNF-a were first implicated in successful vaccination strategies against Leishmania major [15] and later also against MTB [30] . Recently, these polyfunctional CD4 T cells were also detected in TB vaccine trials [31, 32] . We detected polyfunctional CD4 T cells upon rBCG and pBCG vaccination and subsequent infection; however, the composition of cytokines (IL-2, IL-17, IFN-c, and TNF-a) in double and triple producers varied considerably between experiments as well as between individual animals. If multifunctional cells were a true correlate of protection, then their overall frequencies, which were higher in the rBCG group, rather than their composition, seem relevant.
Th17 cells are considered to be instrumental in inflammatory and autoimmune diseases such as collagen-induced arthritis [33] , experimental autoimmune encephalomyelitis (EAE) [33, 34] , and allergic airway hypersensitivity [33, 35] . This pathogenic role is usually associated with development of a profound IL-21-mediated inflammatory response. We never detected IL-21 after vaccination and subsequent MTB infection above background levels (data not shown). A recent report described a pathological role for IL-17 after repeated BCG vaccination and MTB exposure [36] . In contrast, the single administration of rBCG described here elicited a balanced type 1/type 17 cytokine response, and increased IL-17 abundance was only detected prior to and early after MTB infection. During persistent infection, IFN-c and IL-17 production was comparable between the pBCG and rBCG groups. In addition, we never observed signs of autoimmunity or excessive inflammation upon vaccination with rBCG for up to 200 days after MTB infection.
In an attempt to compare data from mouse experiments with data from human studies, we analyzed cytokine profiles of frozen peripheral blood mononuclear cells from a phase I clinical trial with rBCG and pBCG. In a limited number of samples (3 samples from pBCG-vaccinated donors and 7 samples from rBCG-vaccinated donors), we detected IL-17 production after rBCG vaccination but not after pBCG vaccination (data not shown). Th17 cells have been detected in peripheral blood samples from MTB-infected humans [18] . Recently, IL-17-producing CD4 T cells have been reported in samples from adolescents vaccinated with a modified vaccinia virus Ankara expressing Ag85A [32, 37] . Thus, it is tempting to consider IL-17 as a correlate of protection in TB vaccine trials.
Why did rBCG but not pBCG induce IL-17 production? Immunization with rBCG and pBCG caused recruitment of APC as well as chemokine and cytokine producers to a similar extent. Intriguingly, proportions of cd T cells secreting IL-17 and NK cells producing IFN-c were highly abundant after rBCG vaccination. This is consistent with reports that IL-17 is rapidly produced by cd T cells [19, 38] as well as NK T cells [39] . NK cells, counts of which were also increased upon vaccination with rBCG, are an important early source of IFN-c. These initial events could pave the way for the development of a sustained, long-lived memory T-cell response.
We have shown elsewhere that components released from rBCG reside in the cytosol of infected macrophages [12] . Thus, rBCG-derived pathogen-associated molecular patterns could activate intracellular signaling cascades. Nucleotide-binding oligomerization domain (NOD)-2, for example, is a cytosolic pattern recognition receptor and its engagement has been linked to the development of type 17 memory T-cell responses [40] . It is further known that apoptosis induced during bacterial infection promotes generation of Th17 cells [41] . We have obtained evidence that rBCG induces increased apoptosis compared with pBCG [12] , which could contribute to increased development of IL-17-producing T cells. Activation of inflammasomes could also contribute to type 17 responses via production of IL-1b [42] . NOD-like receptor family, pyrin domain-containing 3, for example, has been found to sense the presence of listeriolysin through changes in adenosine triphosphate concentrations [43] . Thus, induction of IL-17 secretion could require a complex interplay of intracellular stimuli and increased apoptosis that are induced upon rBCG but not pBCG vaccination.
In summary, we demonstrate that vaccination with rBCG leads to generation of type 17 cytokine production in addition to profound type 1 cytokine production. The IL-17 produced could enhance recruitment of antigen-specific T cells to the lung. Ultimately, this cascade of events results in earlier containment of MTB and hence to superior protection by rBCG compared with pBCG. Because IL-17 seems to be instrumental for enhanced recruitment of antigen-specific T cells to the sites of MTB replication, future TB vaccines should be tailored to concomitantly induce balanced type 1 and type 17 cytokine responses. 
